Grant Zeng, CFA
Research analyst, CFA, biotech, small-cap

Arrowhead: There Is Still Plenty Of Room For Share Price Appreciation

Since we initiated coverage of Arrowhead Research Corp (NASDAQ:ARWR) in June 2013, ARWR shares have made a significant run from $1.97 all the way to a current $14.46, a huge appreciation of 634%. For Investors who bought ARWR shares when we initiated the coverage, profit taking may sound natural and reasonable. However, we would like to say that there is still plenty of room for share price to appreciate further from current level. Following are our explanation and argument.

(click to enlarge)(click to enlarge)(click to enlarge)

Positive Phase I Data on ARC-520 Validates DPC Platform Technology

On December 9, 2013, Arrowhead presented data from the Phase I clinical study of ARC-520, the company's clinical

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details